Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carbon Dioxide · 1 trial · 1 indication
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked as part of screening survey prior to concept viewing. If the participant answered "I do not purchase any product to relieve congestion" the participant was excluded. Participants could select only one option available.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first use. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. It was done to compare the spray with the product selected by the participant in Q1. There were 11 points between the two products that participants could divide anyways thet wanted (11-0, 10-1, 9-2, 8-3, 7-4 or 6-5 etc). The more the participant liked a product compared to other, the higher the number of points were to be given to that product.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience.This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
A score of 1 indicates that the statement does not apply at all to the product that you used. A score of 7 indicates that it applies completely to it. You can use any score from 1 to 7 to indicate how much or how little you think the statement applies to this product
| Arm | Type | Description |
|---|---|---|
| Treatment Group | EXPERIMENTAL | Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day. |
| Name | Type | Description |
|---|---|---|
| Carbon Dioxide | DRUG | Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds |
Inclusion Criteria: * Participant who demonstrate understanding of, and willingness to participate in the study * Aged at least 18 years. * Understands and is willing, able and likely to comply with all study procedures and restrictions. * Good general and mental health with, in the opinion of the ...
Carbon Dioxide is an investigational small molecule being developed for the treatment of nasal congestion. It is administered as a nasal spray. The drug is currently in Phase 2 clinical development and is not approved for any use.
Carbon Dioxide is being developed by GSK plc, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's potential in treating nasal congestion.
Carbon Dioxide is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Carbon Dioxide has one completed clinical trial, identified as NCT02113449, titled "Market Potential of Carbon Dioxide Nasal Spray." This Phase 2 study enrolled 147 participants in the United States and evaluated the drug for nasal congestion.
Carbon Dioxide is the chemical compound CO2. In the context of this drug, it is being developed as a nasal spray formulation for nasal congestion. The drug is currently in Phase 2 clinical trials and is not approved.